Search

Your search keyword '"AGABITI‐ROSEI, E."' showing total 297 results
Start Over Author "AGABITI‐ROSEI, E." Search Limiters Full Text
297 results on '"AGABITI‐ROSEI, E."'

1. Relationship between salt consumption and iodine intake in a pediatric population

Author

Iacone, R., Iaccarino Idelson, P., Campanozzi, A., Rutigliano, I., Russo, O., Formisano, P., Galeone, D., Macchia, P. E., Strazzullo, P., Agabiti-Rosei, E., Carcea, M., Donfrancesco, C., Galletti, F., Giampaoli, S., Iacoviello, L., Scalfi, L., Siani, A., De Filippo, G., Malamisura, B., Cecere, G., Micillo, M., D'Angelo, E., Maschione, R., De Marco, G., D'Angelo, G., Cosenza, C., Gualano, R., Borsetti, R., Cela, G., Francavilla, R., Tetro, A., Pensabene, L., Talarico, V., Graziano, F., Palermo, B. V. E., Lombardi, G., Illiceto, M. T., Tonelli, L., Catassi, C., Tonelli, G., Castellucci, G., Ferraro, L., Cozzali, R., Di Biase, R., Cipolli, S., Lezo, A., Santini, B., Salvatore, S., Morando, L., Paoletti, S., Gallese, A., Mazzone, T., Iacone, Roberto, IACCARINO IDELSON, Paola, Campanozzi, Angelo, Rutigliano, Irene, Russo, Ornella, Formisano, Pietro, Galeone, Daniela, Macchia, PAOLO EMIDIO, and Strazzullo, Pasquale

Subjects
Adolescent, Endocrinology, Diabetes and Metabolism, Salt (chemistry), Nutritional Status, Medicine (miscellaneous), Context (language use), Sodium Chloride, World health, Animal science, 24 h urinary excretion, Environmental health, salt, Humans, Medicine, Sodium Chloride, Dietary, Salt intake, Child, Iodine intake, chemistry.chemical_classification, Thyroid, Consumption (economics), Nutrition and Dietetics, iodine prophylaxi, business.industry, Salt reduction, Iodine deficiency disorders, Original Contribution, Iodised salt, pediatric, chemistry, Italy, iodine deficiency disorder, Salt restriction, Hypertension, Iodine prophylaxis, Cardiology and Cardiovascular Medicine, business, Pediatric age, Iodine, Pediatric population
Abstract

Purpose The World Health Organization recommends reduction of salt intake to Methods The study population was made of 1270 children and adolescents. Estimates of salt consumption and iodine intake were obtained by measuring 24 h urinary sodium and iodine excretion. Results The iodine intake increased gradually across quartiles of salt consumption independently of sex, age and body weight (p 10.2 g/day). We estimated that approximately 65–73% of the total iodine intake was derived from food and 27–35% from iodized salt and that iodized salt made actually only 20% of the total salt intake. Conclusion In this pediatric population, in face of an elevated average salt consumption, the use of iodized salt was still insufficient to ensure an adequate iodine intake, in particular among teenagers. In the perspective of a progressive reduction of total salt intake, the health institutions should continue to support iodoprophylaxis, in the context of the national strategies for salt reduction. In order for these policies to be successful, in addition to educational campaigns, it is needed that the prescriptions contained in the current legislation on iodoprophylaxis are made compelling through specific enforcement measures for all the involved stakeholders.

Published
2020

5. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease

Author

Borghi C, Agabiti-Rosei E, Johnson R, Kielstein J, Lurbe E, Mancia G, Redon J, Stack A, and Tsioufis K

Subjects
nutritional and metabolic diseases, urologic and male genital diseases
Abstract

During the last century, there has been an increasing prevalence of hyperuricaemia noted in many populations. While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hypertriglyceridaemia, obesity, atherosclerotic heart disease, metabolic syndrome, and type 2 diabetes. Here we review the connection between hyperuricaemia and cardiovascular, kidney and metabolic diseases. Contrary to the popular view that uric acid is an inert metabolite of purine metabolism, recent studies suggest serum uric acid may have a variety of pro-inflammatory, pro-oxidative and vasoconstrictive actions that may contribute to cardiometabolic diseases. Hyperuricaemia is a predictive factor for the development of hypertension, metabolic syndrome, type 2 diabetes, coronary artery disease, left ventricular hypertrophy, atrial fibrillation, myocardial infarction, stroke, heart failure and chronic kidney disease. Treatment with uric acid-lowering therapies has also been found to improve outcomes in patients with hypertension and kidney disease, in some but not all studies. In conclusion, uric acid is emerging as a potentially treatable risk factor for cardiometabolic diseases, and more clinical trials investigating the potential benefit of lowering serum uric acid are recommended in individuals with hyperuricaemia with and without deposition and concomitant hypertension, metabolic syndrome or chronic kidney disease. Copyright © 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Published
2020

6. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease

Author

Borghi, C. Agabiti-Rosei, E. Johnson, R.J. Kielstein, J.T. Lurbe, E. Mancia, G. Redon, J. Stack, A.G. Tsioufis, K.P.

Subjects
nutritional and metabolic diseases, urologic and male genital diseases
Abstract

During the last century, there has been an increasing prevalence of hyperuricaemia noted in many populations. While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hypertriglyceridaemia, obesity, atherosclerotic heart disease, metabolic syndrome, and type 2 diabetes. Here we review the connection between hyperuricaemia and cardiovascular, kidney and metabolic diseases. Contrary to the popular view that uric acid is an inert metabolite of purine metabolism, recent studies suggest serum uric acid may have a variety of pro-inflammatory, pro-oxidative and vasoconstrictive actions that may contribute to cardiometabolic diseases. Hyperuricaemia is a predictive factor for the development of hypertension, metabolic syndrome, type 2 diabetes, coronary artery disease, left ventricular hypertrophy, atrial fibrillation, myocardial infarction, stroke, heart failure and chronic kidney disease. Treatment with uric acid-lowering therapies has also been found to improve outcomes in patients with hypertension and kidney disease, in some but not all studies. In conclusion, uric acid is emerging as a potentially treatable risk factor for cardiometabolic diseases, and more clinical trials investigating the potential benefit of lowering serum uric acid are recommended in individuals with hyperuricaemia with and without deposition and concomitant hypertension, metabolic syndrome or chronic kidney disease. © 2020 European Federation of Internal Medicine

Published
2020

7. Nutraceuticals and blood pressure control: A European Society of Hypertension position document

Author

Borghi, C., Prof. Tsioufis, K. Agabiti-Rosei, E. Burnier, M. Cicero, A.F.G. Clement, D. Coca, A. Desideri, G. Grassi, G. Lovic, D. Lurbe, E. Kahan, T. Kreutz, R. Jelakovic, B. Polonia, J. Redon, J. Van De Borne, P. Mancia, G.

Abstract

High-normal blood pressure (BP) is associated with an increased risk of cardiovascular disease, however the cost-benefit ratio of the use of antihypertensive treatment in these patients is not yet clear. Some dietary components and natural products seems to be able to significantly lower BP without significant side effects. The aim of this position document is to highlight which of these products have the most clinically significant antihypertensive action and wheter they could be suggested to patients with high-normal BP. Among foods, beetroot juice has the most covincing evidence of antihypertensive effect. Antioxidant-rich beverages (teas, coffee) could be considered. Among nutrients, magnesium, potassium and vitamin C supplements could improve BP. Among nonnutrient-nutraceuticals, soy isoflavones could be suggested in perimenopausal women, resveratrol in insulin-resistant patients, melatonin in study participants with night hypertension. In any case, the nutracutical approach has never to substitute the drug treatment, when needed. © 2020 Lippincott Williams and Wilkins. All rights reserved.

Published
2020

15. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH)

Author

Perrone-Filardi P, Coca A, Galderisi M, Paolillo S, Alpendurada F, de Simone G, Donal E, Kahan T, Mancia G, Redon J, Schmieder R, Williams B, Agabiti-Rosei E, Perrone Filardi, P, Coca, A, Galderisi, M, Paolillo, S, Alpendurada, F, De Simone, G, Donal, E, Kahan, T, Mancia, G, Redon, J, Schmieder, R, Williams, B, and Agabiti Rosei, E

Subjects
cardiovascular risk, Male, arterial hypertension, Consensus, Cardiology, Risk Assessment, Europe, Cardiac Imaging Techniques, Cardiovascular Diseases, target organ damage, Asymptomatic Diseases, Hypertension, Practice Guidelines as Topic, Humans, Female, non-invasive cardiovascular imaging, prognosi, Societies, Medical
Abstract

Arterial hypertension (HTN) accounts for the largest amount of attributable cardiovascular (CV) mortality worldwide, and risk stratification in hypertensive patients is of crucial importance to manage treatment and prevent adverse events. Asymptomatic involvement of different organs in patients affected by HTN represents an independent determinant of CV risk and the identification of target organ damage (TOD) is recommended to further reclassify patients' risk. Non-invasive CV imaging is progressively being used and continues to provide new technological opportunities to TOD evaluation at early stage. The aim of this article is to provide the community of cardiology with an update on appropriate and justified use of non-invasive imaging tests in the growing population of hypertensive patients.

Published
2017

17. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: A randomised controlled trial protocol

Author

Parati, G. Agabiti-Rosei, E. Bakris, G.L. Bilo, G. Branzi, G. Cecchi, F. Chrostowska, M. De La Sierra, A. Domenech, M. Dorobantu, M. Faria, T. Huo, Y. Jelaković, B. Kahan, T. Konradi, A. Laurent, S. Li, N. Madan, K. Mancia, G. McManus, R.J. Modesti, P.A. Ochoa, J.E. Octavio, J.A. Omboni, S. Palatini, P. Park, J.B. Pellegrini, D. Perl, S. Podoleanu, C. Pucci, G. Redon, J. Renna, N. Rhee, M.Y. Rodilla Sala, E. Sanchez, R. Schmieder, R. Soranna, D. Stergiou, G. Stojanovic, M. Tsioufis, K. Valsecchi, M.G. Veglio, F. Waisman, G.D. Wang, J.G. Wijnmaalen, P. Zambon, A. Zanchetti, A. Zhang, Y.

Abstract

Introduction Masked uncontrolled hypertension (MUCH) carries an increased risk of cardiovascular (CV) complications and can be identified through combined use of office (O) and ambulatory (A) blood pressure (BP) monitoring (M) in treated patients. However, it is still debated whether the information carried by ABPM should be considered for MUCH management. Aim of the MASked-unconTrolled hypERtension management based on OBP or on ambulatory blood pressure measurement (MASTER) Study is to assess the impact on outcome of MUCH management based on OBPM or ABPM. Methods and analysis MASTER is a 4-year prospective, randomised, open-label, blinded-endpoint investigation. A total of 1240 treated hypertensive patients from about 40 secondary care clinical centres worldwide will be included -upon confirming presence of MUCH (repeated on treatment OBP

Published
2018

18. Should renal color Doppler ultrasonography be a routine test in newly diagnosed hypertensive patient?

Author

Tsioufis, C. Andrikou, I. Pruijm, M. Ponte, B. Sarafidis, P. Koureas, A. Tousoulis, D. Agabiti-Rosei, E. Mancia, G. Burnier, M.

Abstract

European Society of Hypertension/European Society of Cardiology guidelines recommend calculation of estimated glomerular filtration rate and evaluation of urinary albumin excretion rate as routine tests in the initial evaluation and during the follow-up of all hypertensive patients. However, from a clinical point of view, renal ultrasound-a noninvasive, readily available and cheap imaging modality-could contribute to the better evaluation of a hypertensive patient by identifying common causes of secondary hypertension (HTN) originating from the kidney and more recently by detecting renal injury in severe or long-standing essential HTN by measuring renal resistive indexes. The purpose of this review is to summarize the actual evidence which could support a larger use of renal ultrasound in the work-up of patients with newly diagnosed HTN. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

Published
2018

19. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC)

Author

Williams, B. Mancia, G. Spiering, W. Agabiti Rosei, E. Azizi, M. Burnier, M. Clement, D. Coca, A. De Simone, G. Dominiczak, A. Kahan, T. Mahfoud, F. Redon, J. Ruilope, L. Zanchetti, A. Kerins, M. Kjeldsen, S. Kreutz, R. Laurent, S. Lip, G.Y.H. McManus, R. Narkiewicz, K. Ruschitzka, F. Schmieder, R. Shlyakhto, E. Tsioufis, K. Aboyans, V. Desormais, I.

Abstract

These practice guidelines on the management of arterial hypertension are a concise summary of the more extensive ones prepared by the Task Force jointly appointed by the European Society of Hypertension and the European Society of Cardiology. These guidelines have been prepared on the basis of the best available evidence on all issues deserving recommendations; their role must be educational and not prescriptive or coercive for the management of individual subjects who may differ widely in their personal, medical and cultural characteristics. The members of the Task Force have participated independently in the preparation of these guidelines, drawing on their academic and clinical experience and by objective examination and interpretation of all available literature. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

Published
2018

20. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment

Author

Danaei, G, Lu, Y, Singh, Gm, Carnahan, E, Stevens, Ga, Cowan, Mj, Farzadfar, F, Lin, Jk, Finucane, Mm, Rao, M, Khang, Yh, Riley, Lm, Mozaffarian, D, Lim, Ss, Ezzati, M, Aamodt, G, Abdeen, Z, Abdella, Na, Rahim, Hf, Addo, J, Aekplakorn, W, Afifi, Mm, Agabiti Rosei, E, Salinas, Ca, Agyemang, C, Ali, Mk, Ali, Mm, Al Nsour, M, Al Nuaim AR, Ambady, R, Di Angelantonio, E, Aro, P, Azizi, F, Babu, Bv, Bahalim, An, Barbagallo, Cm, Barbieri, Ma, Barceló, A, Barreto, Sm, Barros, H, Bautista, Le, Benetos, A, Bjerregaard, P, Björkelund, C, Bo, S, Bobak, M, Bonora, Enzo, Botana, Ma, Bovet, P, Breckenkamp, J, Breteler, Mm, Broda, G, Brown, Ij, Bursztyn, M, de León AC, Campos, H, Cappuccio, Fp, Capuano, V, Casiglia, E, Castellano, M, Castetbon, K, Cea, L, Chang, Cj, Chaouki, N, Chatterji, S, Chen, Cj, Chen, Z, Choi, Js, Chua, L, Cífková, R, Cobiac, Lj, Cooper, Rs, Corsi, Am, Costanza, Mc, Craig, Cl, Dankner, Rs, Dastgiri, S, Delgado, E, Dinc, G, Doi, Y, Dong, Gh, Dorsi, E, Dragano, N, Drewnowski, A, Eggertsen, R, Elliott, P, Engeland, A, Erem, C, Esteghamati, A, Fall, Ch, Fan, Jg, Ferreccio, C, Fezeu, L, Firmo, Jo, Florez, Hj, Fornés, Ns, Fowkes, Fg, Franceschini, G, Frisk, F, Fuchs, Fd, Fuller, El, Getz, L, Giampaoli, S, Gómez, Lf, Gomez Zumaquero JM, Graff Iversen, S, Grant, Jf, Carvajal, Rg, Gulliford, Mc, Gupta, R, Gupta, Pc, Gureje, O, Gutierrez, Hr, Hansen, Tw, Hata, J, He, J, Heim, N, Heinrich, J, Hemmingsson, T, Hennis, A, Herman, Wh, Herrera, Vm, Ho, S, Holdsworth, M, Frisman, Gh, Hopman, Wm, Hussain, A, Husseini, A, Ibrahim, Mm, Ikeda, N, Jacobsen, Bk, Jaddou, Hy, Jafar, Th, Janghorbani, M, Jasienska, G, Joffres, Mr, Jonas, Jb, Kadiki, Oa, Kalter Leibovici, O, Kamadjeu, Rm, Kaptoge, S, Karalis, I, Kastarinen, Mj, Katz, J, Keinan Boker, L, Kelly, P, Khalilzadeh, O, Kiechl, S, Kim, Kw, Kiyohara, Y, Kobayashi, J, Krause, Mp, Kubínová, R, Kurjata, P, Kusuma, Ys, Lam, Th, Langhammer, A, Lawes, Cm, Le, C, Lee, J, Lévy Marchal, C, Lewington, S, Li, Y, Lim, To, Lin, X, Lin, Cc, Lin, Hh, Lind, L, Lissner, L, Liu, X, Lopez Jaramillo, P, Lorbeer, R, Ma, G, Ma, S, Macià, F, Maclean, Dr, Maggi, S, Magliano, Dj, Makdisse, M, Mancia, G, Mannami, T, Marques Vidal, P, Mbanya, Jc, McFarlane Anderson, N, Miccoli, R, Miettola, J, Minh, Hv, Miquel, Jf, Miranda, Jj, Mohamed, Mk, Mohan, V, Mohanna, S, Mokdad, A, Mollentze, Wf, Morales, Dd, Morgan, K, Muiesan, Lm, Muntoni, S, Nabipour, I, Nakagami, T, Nangia, V, Nemesure, B, Neovius, M, Nerhus, Ka, Nervi, F, Neuhauser, H, Nguyen, M, Ninomiya, T, Noale, M, Oh, Sw, Ohkubo, T, Olivieri, Oliviero, Önal, Ae, Onat, A, Oróstegui, M, Ouedraogo, H, Pan, Wh, Panagiotakos, Db, Panza, F, Park, Y, Passos, Vm, Pednekar, Ms, Pelizzari, Pm, Peres, Ma, Pérez, C, Pérez Fernández, R, Pichardo, R, Phua, Hp, Pistelli, F, Plans, P, Polakowska, M, Poulter, N, Prabhakaran, D, Qiao, Q, Rafiei, M, Raitakari, Ot, Ramos, Lr, Rampal, S, Rampal, L, Rasmussen, F, Reddy, Kk, Redon, J, Revilla, L, Reyes García, V, Roaeid, Rb, Robinson, Ca, Rodriguez Artalejo, F, Rojas Martinez, R, Ronkainen, K, Rosero Bixby, L, Roth, Ga, Sachdev, Hs, Sánchez, Jr, Sanisoglu, Sy, Sans, S, Sarraf Zadegan, N, Scazufca, M, Schaan, Bd, Schapochnik, N, Schelleman, H, Schneider, Ij, Schooling, Cm, Schwarz, B, Sekuri, C, Sereday, Ms, Serra Majem, L, Shaw, J, Shera, As, Shi, Z, Shiri, R, Shu, Xo, Silva, Da, Silva, E, Simons, La, Smith, M, Söderberg, S, Soebardi, S, Solfrizzi, V, Sonestedt, E, Soysal, A, Stattin, P, Stein, Ad, Stergiou, Gs, Stessman, J, Sudo, A, Suka, M, Sundh, V, Sundquist, K, Sundström, J, Swai, Ab, Tai, Es, Tambs, K, Tesfaye, F, Thomas, Gn, Thorogood, M, Tilvis, Rs, Tobias, M, Torheim, Le, Trenkwalder, P, Tuomilehto, Jo, Tur, Ja, Tzourio, C, Uhernik, Ai, Ukoli, Fa, Unwin, N, Hoorn, Sv, Vanderpump, Mp, Varo, Jj, Veierød, Mb, Velásquez Meléndez, G, Verschuren, M, Viet, L, Villalpando, S, Vioque, J, Vollenweider, P, Volpato, S, Wang, N, Wang, Yx, Ward, M, Waspadji, S, Welin, Lx, Whitlock, G, Wilhelmsen, L, Willeit, J, Woodward, M, Wormser, D, Xavier, Aj, Xu, F, Xu, L, Yamamoto, A, Yang, G, Yang, X, Yeh, Lc, Yoon, Js, You, Q, Yu, Z, Zhang, J, Zhang, L, Zheng, W, Zhou, M, Ward, M., Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration, Danaei, G., Lu, Y., Singh, G.M., Carnahan, E., Stevens, G.A., Cowan, M.J., Farzadfar, F., Lin, J.K., Finucane, M.M., Rao, M., Khang, Y.H., Riley, L.M., Mozaffarian, D., Lim, S.S., Ezzati, M., Aamodt, G., Abdeen, Z., Abdella, N.A., Rahim, H.F., Addo, J., Aekplakorn, W., Afifi, M.M., Agabiti-Rosei, E., Salinas, C.A., Agyemang, C., Ali, M.K., Ali, M.M., Al-Nsour, M., Al-Nuaim, A.R., Ambady, R., Di Angelantonio, E., Aro, P., Azizi, F., Babu, B.V., Bahalim, A.N., Barbagallo, C.M., Barbieri, M.A., Barceló, A., Barreto, S.M., Barros, H., Bautista, L.E., Benetos, A., Bjerregaard, P., Björkelund, C., Bo, S., Bobak, M., Bonora, E., Botana, M.A., Bovet, P., Breckenkamp, J., Breteler, M.M., Broda, G., Brown, I.J., Bursztyn, M., de León, A.C., Campos, H., Cappuccio, F.P., Capuano, V., Casiglia, E., Castellano, M., Castetbon, K., Cea, L., Chang, C.J., Chaouki, N., Chatterji, S., Chen, C.J., Chen, Z., Choi, J.S., Chua, L., Cífková, R., Cobiac, L.J., Cooper, R.S., Corsi, A.M., Costanza, M.C., Craig, C.L., Dankner, R.S., Dastgiri, S., Delgado, E., Dinc, G., Doi, Y., Dong, G.H., Dorsi, E., Dragano, N., Drewnowski, A., Eggertsen, R., Elliott, P., Engeland, A., Erem, C., Esteghamati, A., Fall, C.H., Fan, J.G., Ferreccio, C., Fezeu, L., Firmo, J.O., Florez, H.J., Fornés, N.S., Fowkes, F.G., Franceschini, G., Frisk, F., Fuchs, F.D., Fuller, E.L., Getz, L., Giampaoli, S., Gómez, L.F., Gomez-Zumaquero, J.M., Graff-Iversen, S., Grant, J.F., Carvajal, R.G., Gulliford, M.C., Gupta, R., Gupta, P.C., Gureje, O., Gutierrez, H.R., Hansen, T.W., Hata, J., He, J., Heim, N., Heinrich, J., Hemmingsson, T., Hennis, A., Herman, W.H., Herrera, V.M., Ho, S., Holdsworth, M., Frisman, G.H., Hopman, W.M., Hussain, A., Husseini, A., Ibrahim, M.M., Ikeda, N., Jacobsen, B.K., Jaddou, H.Y., Jafar, T.H., Janghorbani, M., Jasienska, G., Joffres, M.R., Jonas, J.B., Kadiki, O.A., Kalter-Leibovici, O., Kamadjeu, R.M., Kaptoge, S., Karalis, I., Kastarinen, M.J., Katz, J., Keinan-Boker, L., Kelly, P., Khalilzadeh, O., Kiechl, S., Kim, K.W., Kiyohara, Y., Kobayashi, J., Krause, M.P., Kubínová, R., Kurjata, P., Kusuma, Y.S., Lam, T.H., Langhammer, A., Lawes, C.M., Le, C., Lee, J., Lévy-Marchal, C., Lewington, S., Li, Y., Lim, T.O., Lin, X., Lin, C.C., Lin, H.H., Lind, L., Lissner, L., Liu, X., Lopez-Jaramillo, P., Lorbeer, R., Ma, G., Ma, S., Macià, F., MacLean, D.R., Maggi, S., Magliano, D.J., Makdisse, M., Mancia, G., Mannami, T., Marques-Vidal, P., Mbanya, J.C., McFarlane-Anderson, N., Miccoli, R., Miettola, J., Minh, H.V., Miquel, J.F., Miranda, J.J., Mohamed, M.K., Mohan, V., Mohanna, S., Mokdad, A., Mollentze, W.F., Morales, D.D., Morgan, K., Muiesan, L.M., Muntoni, S., Nabipour, I., Nakagami, T., Nangia, V., Nemesure, B., Neovius, M., Nerhus, K.A., Nervi, F., Neuhauser, H., Nguyen, M., Ninomiya, T., Noale, M., Oh, S.W., Ohkubo, T., Olivieri, O., Önal, A.E., Onat, A., Oróstegui, M., Ouedraogo, H., Pan, W.H., Panagiotakos, D.B., Panza, F., Park, Y., Passos, V.M., Pednekar, M.S., Pelizzari, P.M., Peres, M.A., Pérez, C., Pérez-Fernández, R., Pichardo, R., Phua, H.P., Pistelli, F., Plans, P., Polakowska, M., Poulter, N., Prabhakaran, D., Qiao, Q., Rafiei, M., Raitakari, O.T., Ramos, L.R., Rampal, S., Rampal, L., Rasmussen, F., Reddy, K.K., Redon, J., Revilla, L., Reyes-García, V., Roaeid, R.B., Robinson, C.A., Rodriguez-Artalejo, F., Rojas-Martinez, R., Ronkainen, K., Rosero-Bixby, L., Roth, G.A., Sachdev, H.S., Sánchez, J.R., Sanisoglu, S.Y., Sans, S., Sarraf-Zadegan, N., Scazufca, M., Schaan, B.D., Schapochnik, N., Schelleman, H., Schneider, I.J., Schooling, C.M., Schwarz, B., Sekuri, C., Sereday, M.S., Serra-Majem, L., Shaw, J., Shera, A.S., Shi, Z., Shiri, R., Shu, X.O., Silva, D.A., Silva, E., Simons, L.A., Smith, M., Söderberg, S., Soebardi, S., Solfrizzi, V., Sonestedt, E., Soysal, A., Stattin, P., Stein, A.D., Stergiou, G.S., Stessman, J., Sudo, A., Suka, M., Sundh, V., Sundquist, K., Sundström, J., Swai, A.B., Tai, E.S., Tambs, K., Tesfaye, F., Thomas, G.N., Thorogood, M., Tilvis, R.S., Tobias, M., Torheim, L.E., Trenkwalder, P., Tuomilehto, J.O., Tur, J.A., Tzourio, C., Uhernik, A.I., Ukoli, F.A., Unwin, N., Hoorn, S.V., Vanderpump, M.P., Varo, J.J., Veierød, M.B., Velásquez-Meléndez, G., Verschuren, M., Viet, L., Villalpando, S., Vioque, J., Vollenweider, P., Volpato, S., Wang, N., Wang, Y.X., Ward, M., Waspadji, S., Welin, L.X., Whitlock, G., Wilhelmsen, L., Willeit, J., Woodward, M., Wormser, D., Xavier, A.J., Xu, F., Xu, L., Yamamoto, A., Yang, G., Yang, X., Yeh, L.C., Yoon, J.S., You, Q., Yu, Z., Zhang, J., Zhang, L., Zheng, W., Zhou, M., ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, Public and occupational health, Danaei G, Lu Y, Singh GM, Stevens GA, Cowan MJ, Farzadfar F, Lin JK, Finucane MM, Rao M, Khang Y-H, Riley LM, Mozaffarian D, Lim SS, Ezzati M, Aamodt G, Abdeen Z, Abdella NA, Abdul Rahim HF, Addo J, Aekplakorn W, Afi fi MM, Agabiti-Rosei E, Aguilar Salinas CA, Agyemang C, Ali MK, Ali MM, Al-Nsour M, Al-Nuaim AR, Ambady R, Di Angelantonio E, Aro P, Azizi F, Babu BV, Bahalim AN, Barbagallo CM, Barbieri MA, Barcelo A, Barreto SM, Barros H, Bautista LE, Benetos A, Bjerregaard P, Bjorkelund C, Bo S, Bobak M, Bonora E, Botana MA, Bovet P, Breckenkamp J, Breteler MM, Broda G, Brown IJ, Bursztyn M, Cabrera de Leon A, Campos H, Cappuccio FP, Capuano V, Casiglia E, Castellano M, Castetbon K, Cea L, Chang C-J, Chaouki N, Chatterji S, Chen C-J, Chen Z, Choi J-S, Chua L, Cifkova R, Cobiac LJ, Cooper RS, Corsi AM, Costanza MC, Craig CL, Dankner RS, Dastgiri S, Delgado E, Dinc G, Doi Y, Dong G-H, Dorsi E, Dragano N, Drewnowski A, Eggertsen R, Elliott P, Anders Engeland, Erem C, Esteghamati A, Fall CHD, Fan J-G, Ferreccio C, Fezeu L, Firmo JO, Florez HF, Fornes NF, Fowkes FGR, Franceschini G, Frisk F, Fuchs FD, Fuller EL, Getz L, Giampaoli S, Gomez LF, Gomez-Zumaquero JM, Graff –Iversen S, Grant JF, Guerrero Carvajal R, Gulliford MC, Gupta R, Gupta PC, Gureje O, Gutierrez HR, Hansen TW, Hata J, He J, Heim N, Heinrich J, Hemmingsson T, Hennis A, Herman WH, Herrera VM, Ho S, Holdsworth M, Hollman Frisman G, Hopman WM, Hussain A, Husseini A, Ibrahim MM, Ikeda N, Jacobsen BK, Jaddou HY, Jafar TH, Janghorbani M, Jasienska G, Joffres MR, Jonas JB, Kadiki OA, Kalter-Leibovici O, Kamadjeu RM, Kaptoge S, Karalis I, Kastarinen MJ, Katz J, Keinan-Boker L, Kelly P, Khalilzadeh O, Kiechl S, Woong Kim KW, Kiyohara Y, Kobayashi J, Krause MP, Kubinova R, Kurjata P, Kusuma YS, Lam TH, Langhammer A, Lawes CMM, Le C, Lee J, Levy-Marchal C, Lewington S, Li Y, Lim TO, Lin X, Lin C-C, Lin H-H, Lind L, Lissner L, Liu X, Lopez-Jaramillo P, Lorbeer R, Ma G, Ma S, Macia F, MacLean DR, Maggi S, Magliano DJ, Makdisse M, Mancia G, Mannami T, Marques-Vidal P, Mbanya JCN, McFarlane-Anderson N, Miccoli R, Miettola J, Minh HV, Miquel JF, J Miranda JJ, Mohamed MK, Mohan V, Mohanna S, Mokdad A, Mollentze WF, Morales DD, Morgan K, Muiesan LM, Muntoni S, Nabipour I, Nakagami T, Nangia V, Nemesure B, Neovius M, Nerhus KA, Nervi F, Neuhauser H, Nguyen M, Ninomiya T, Noale M, Oh SW, Ohkubo T, Olivieri O, Onal AE, Onat A, Orostegui M, Ouedraogo H, Pan W-A, Panagiotakos DB, Panza F, Park Y, Passos VMA, Pednekar MS, Pelizzari PM, Peres MA, Perez C, Perez-Fernandez R, Pichardo R, Hwee Pin Phua, Francesco Pistelli, Plans P, Polakowska M, Poulter N, Prabhakaran D, Qiao Q, Rafiei M, Raitakari OT, Ramos LR, Rampal S, Rampal L, Rasmussen F, Reddy KKR, Josep Redon J, Revilla L, Reyes-GarciaV, Roaeid RB, Robinson CA, Rodriguez-Artalejo F, Rojas-Martinez R, Ronkainen K, Rosero-Bixby L, Roth GA, Sachdev HS, Sanchez JR, Sanisoglu SY, Sans S, Sarraf-Zadegan N, Scazufca M, Schaan BD, Schapochnik N, Schelleman H, Schneider IJC, Schooling CM, Schwarz B, Sekuri C, Sereday MS, Serra-Majem L, Shaw J, Shera AS, Shi Z, Shiri R, Shu XO, Santos Silva DA, Silva E, Simons LA, Smith M, Soderberg S, Soebardi S, Solfrizzi V, Sonestedt E, Soysal A, StattinP, Stein AD, Stergiou GS, Stessman J, Sudo A, Suka M, Sundh V, Sundquist K, Sundstrom J, Swai AB, Tai ES, Tambs K, Tesfaye F, Thomas GN, Thorogood M, Tilvis RS, Tobias M, Torheim LE, Trenkwalder P, Tuomilehto JO, Tur JA, Tzourio C, Uhernik A, Ukoli FA, Unwin N, Vander Hoorn S, Vanderpump MP, Varo JJ, Veierod MB, Velasquez-Melendez G, Verschuren M, Viet L, Villalpando S, Vioque J, Vollenweider P, Volpato S, Wang N, Wang YX, Ward M, Waspadji S, Welin LX, Whitlock G, Wilhelmsen L, Willeit J, Woodward M, Wormser D, Xavier AJ, Xu F, Xu L, Yamamoto A, Yang G, Yang X, Yeh L-C, Yoon J-S, You Q, Yu Z, Zhang J, Zhang L, Zheng W, Zhou M, Danaei, G, Lu, Y, Singh, G, Carnahan, E, Stevens, G, Cowan, M, Farzadfar, F, Lin, J, Finucane, M, Rao, M, Khang, Y, Riley, L, Arian, D, Lim, S, Ezzati, M, Aamodt, G, Abdeen, Z, Abdella, N, Rahim, H, Addo, J, Aekplakorn, W, Afifi, M, Agabiti-Rosei, E, Salinas, C, Agyemang, C, Ali, M, Al-Nsour, M, Al-Nuaim, A, Ambady, R, Angelantonio, E, Aro, P, Azizi, F, Babu, B, Bahalim, A, Barbagallo, C, Barbieri, M, Barceló, A, Barreto, S, Barros, H, Bautista, L, Benetos, A, Bjerregaard, P, Björkelund, C, Bo, S, Bobak, M, Bonora, E, Botana, M, Bovet, P, Breckenkamp, J, Breteler, M, Broda, G, Brown, I, Bursztyn, M, de León, A, Campos, H, Cappuccio, F, Capuano, V, Casiglia, E, Castellano, M, Castetbon, K, Cea, L, Chang, C, Chaouki, N, Chatterji, S, Chen, C, Chen, Z, Choi, J, Chua, L, Cífková, R, Cobiac, L, Cooper, R, Corsi, A, Costanza, M, Craig, C, Dankner, R, Dastgiri, S, Delgado, E, Dinc, G, Doi, Y, Dong, G, Dorsi, E, Dragano, N, Drewnowski, A, Eggertsen, R, Elliott, P, Engeland, A, Erem, C, Esteghamati, A, Fall, C, Fan, J, Ferreccio, C, Fezeu, L, Firmo, J, Florez, H, Fornés, N, Fowkes, F, Franceschini, G, Frisk, F, Fuchs, F, Fuller, E, Getz, L, Giampaoli, S, Gómez, L, Gomez-Zumaquero, J, Iversen, S, Grant, J, Carvajal, R, Gulliford, M, Gupta, R, Gupta, P, Gureje, O, Gutierrez, H, Hansen, T, Hata, J, He, J, Heim, N, Heinrich, J, Hemmingsson, T, Hennis, A, Herman, W, Herrera, V, Ho, S, Holdsworth, M, Frisman, G, Hopman, W, Hussain, A, Husseini, A, Ibrahim, M, Ikeda, N, Jacobsen, B, Jaddou, H, Jafar, T, Janghorbani, M, Jasienska, G, Joffres, M, Jonas, J, Kadiki, O, Kalter-Leibovici, O, Kamadjeu, R, Kaptoge, S, Karalis, I, Kastarinen, M, Katz, J, Keinan-Boker, L, Kelly, P, Khalilzadeh, O, Kiechl, S, Kim, K, Kiyohara, Y, Kobayashi, J, Krause, M, Kubínová, R, Kurjata, P, Kusuma, Y, Lam, T, Langhammer, A, Lawes, C, Le, C, Lee, J, Lévy-Marchal, C, Lewington, S, Li, Y, Lim, T, Lin, X, Lin, C, Lin, H, Lind, L, Lissner, L, Liu, X, Lopez-Jaramillo, P, Lorbeer, R, Ma, G, Ma, S, Macià, F, Maclean, D, Maggi, S, Magliano, D, Makdisse, M, Mancia, G, Mannami, T, Marques-Vidal, P, Mbanya, J, McFarlane-Anderson, N, Miccoli, R, Miettola, J, Minh, H, Miquel, J, Miranda, J, Mohamed, M, Mohan, V, Mohanna, S, Mokdad, A, Mollentze, W, Morales, D, Morgan, K, Lorenza M Muiesan, N, Muntoni, S, Nabipour, I, Nakagami, T, Nangia, V, Nemesure, B, Neovius, M, Nerhus, K, Nervi, F, Neuhauser, H, Nguyen, M, Ninomiya, T, Noale, M, Oh, S, Ohkubo, T, Olivieri, O, Önal, A, Onat, A, Oróstegui, M, Ouedraogo, H, Pan, W, Panagiotakos, D, Panza, F, Park, Y, Passos, V, Pednekar, M, Pelizzari, P, Peres, M, Cynthia Pérez, N, Pérez-Fernández, R, Pichardo, R, Phua, H, Pistelli, F, Plans, P, Polakowska, M, Poulter, N, Prabhakaran, D, Qiao, Q, Rafiei, M, Raitakari, O, Ramos, L, Rampal, S, Rampal, L, Rasmussen, F, Reddy, K, Redon, J, Revilla, L, Reyes-García, V, Roaeid, R, Robinson, C, Rodriguez-Artalejo, F, Rojas-Martinez, R, Ronkainen, K, Rosero-Bixby, L, Roth, G, Sachdev, H, Sánchez, J, Sanisoglu, S, Sans, S, Sarraf-Zadegan, N, Scazufca, M, Schaan, B, Schapochnik, N, Schelleman, H, Schneider, I, Schooling, C, Schwarz, B, Sekuri, C, Sereday, M, Serra-Majem, L, Shaw, J, Shera, A, Shi, Z, Shiri, R, Shu, X, Silva, D, Silva, E, Simons, L, Smith, M, Söderberg, S, Soebardi, S, Solfrizzi, V, Sonestedt, E, Soysal, A, Stattin, P, Stein, A, Stergiou, G, Stessman, J, Sudo, A, Suka, M, Sundh, V, Sundquist, K, Sundström, J, Swai, A, Tai, E, Tambs, K, Tesfaye, F, Thomas, G, Thorogood, M, Tilvis, R, Tobias, M, Torheim, L, Trenkwalder, P, Tuomilehto, J, Tur, J, Tzourio, C, Uhernik, A, Ukoli, F, Unwin, N, Hoorn, S, Vanderpump, M, Varo, J, Veierød, M, Velásquez-Meléndez, G, Verschuren, M, Viet, L, Villalpando, S, Vioque, J, Vollenweider, P, Volpato, S, Wang, N, Wang, Y, Ward, M, Waspadji, S, Lennart X Welin, N, Whitlock, G, Wilhelmsen, L, Willeit, J, Woodward, M, Wormser, D, André J Xavier, N, Xu, F, Xu, L, Yamamoto, A, Yang, G, Yang, X, Yeh, L, Yoon, J, You, Q, Yu, Z, Zhang, J, Zhang, L, Zheng, W, and Zhou, M

Subjects
Male, Settore MED/09 - Medicina Interna, kidney disease, Endocrinology, Diabetes and Metabolism, humanos, coste de las enfermedades, Disease, Global Health, Cohort Studies, Endocrinology, Cost of Illness, cardiovascular disease, Health Transition, Risk Factors, transición sanitaria, estudios prospectivos, Renal Insufficiency, Chronic -- complications -- epidemiology -- mortality, evaluación de riesgos, Renal Insufficiency, Prospective Studies, Chronic, estudios de cohortes, Metabolic Syndrome, education.field_of_study, diabetes, Mortality rate, Age Factors, Cardiovascular Diseases, Diabetes Complications, Female, Health Surveys, Humans, Metabolic Syndrome X, Renal Insufficiency, Chronic, Risk Assessment, Sex Factors, Spatio-Temporal Analysis, Internal Medicine, Cardiovascular Diseases -- complications -- epidemiology -- mortality, Cardiovascular disease,Diabetes Mellitus, chronic kidney disease, Diabetes Complications -- epidemiology -- mortality, Sciences bio-médicales et agricoles, Diabetes and Metabolism, encuestas de salud, análisis temporoespacial, Risk assessment, complicaciones de la diabetes, insuficiencia renal, medicine.medical_specialty, Cardiovascular disease, diabetes mortality, Population, enfermedades cardiovasculares, Metabolic Syndrome X -- complications -- epidemiology -- mortality, Article, chronic kidney disease, mortality, Internal medicine, Environmental health, Diabetes mellitus, medicine, factores de riesgo, Risk factor, education, business.industry, medicine.disease, Relative risk, Cardiovascular Diseases/complications, Cardiovascular Diseases/epidemiology, Cardiovascular Diseases/mortality, Diabetes Complications/epidemiology, Diabetes Complications/mortality, Metabolic Syndrome X/complications, Metabolic Syndrome X/epidemiology, Metabolic Syndrome X/mortality, Renal Insufficiency, Chronic/complications, Renal Insufficiency, Chronic/epidemiology, Renal Insufficiency, Chronic/mortality, business, Kidney disease
Abstract

High blood pressure, blood glucose, serum cholesterol, and BMI are risk factors for cardiovascular diseases and some of these factors also increase the risk of chronic kidney disease and diabetes. We estimated mortality from cardiovascular diseases, chronic kidney disease, and diabetes that was attributable to these four cardiometabolic risk factors for all countries and regions from 1980 to 2010., 0, info:eu-repo/semantics/published

Published
2014

21. No Longer a Sine Qua Non for Guideline Authors?

Author

Messerli, FH, Hofstetter, L, Agabiti-Rosei, E, Burnier, M, Elliott, WJ, Franklin, SS, Grodzicki, T, Kario, K, Kjeldsen, SE, Kostis, JB, Laurent, S, Leenen, FH, Lund-Johansen, P, Mancia, G, Narkiewicz, K, Papademetriou, V, Parati, G, Poulter, N, Redon, J, Rimoldi, SF, Ruilope, LM, Schiffrin, EL, Schmieder, RE, Schwartz, AB, Sever, P, Sowers, JR, Staessen, JA, Wang, J, Weber, M, and Williams, B

Subjects
OLDER, Science & Technology, HYPERTENSION, 1103 Clinical Sciences, AGED 60 YEARS, 1102 Cardiovascular Medicine And Haematology, Peripheral Vascular Disease, Cardiovascular System & Hematology, Cardiovascular System & Cardiology, BLOOD-PRESSURE TARGETS, INHIBITORS, Life Sciences & Biomedicine, METAANALYSIS, ANGIO-EDEMA
Published
2017

23. Erratum to: Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized 'Z' Studies (Adv Ther, (2017), 34, (784-798), 10.1007/s12325-017-0497-8)

Author

Omboni, S. Malacco, E. Napoli, C. Modesti, P.A. Manolis, A. Parati, G. Agabiti-Rosei, E. Borghi, C.

Abstract

Author wants to correct the text under the heading of Introduction. The sentence is written as: “In the ZENITH study, both treatments had a similar positive effect on regression of cardiac and renal damage, whereas a larger proportion of patients showing carotid plaque regression was observed under zofenopril (31.6% vs. 16.1%; p = 0.047), particularly in the subgroup of patients taking the low dose of zofenopril (30 mg) plus HCTZ 12.5 mg (4.7% vs 10.0% irbesartan 150 mg plus HCTZ 12.5 mg; p = 0.043)”. The correct sentence should read: “In the ZENITH study, both treatments had a similar positive effect on regression of cardiac. © 2017, The Author(s).

Published
2017

24. Who is an expert? Reply

Author

Messerli, FH, Hofstetter, L, Agabiti-Rosei, E, Burnier, M, Elliott, WJ, Franklin, SS, Grodzicki, T, Kario, K, Kjeldsen, SE, Kostis, JB, Laurent, S, Leenen, FH, De Leeuw, PW, Lund-Johansen, P, Mancia, G, Narkiewicz, K, Papademetriou, V, Parati, G, Poulter, N, Redon, J, Rimoldi, SF, Ruilope, LM, Schiffrin, EL, Schmieder, RE, Schwartz, AB, Sever, P, Sowers, JR, Staessen, JA, Wang, J, Weber, M, Williams, B, MUMC+: MA Alg Interne Geneeskunde (9), and RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience

Subjects
OLDER, Science & Technology, Peripheral Vascular Disease, Cardiovascular System & Hematology, HYPERTENSION, Cardiovascular System & Cardiology, 1103 Clinical Sciences, GUIDELINES, Life Sciences & Biomedicine, 1102 Cardiovascular Medicine And Haematology
Abstract

ispartof: Journal of Hypertension vol:35 issue:11 pages:2327-2328 ispartof: location:Netherlands status: published

Published
2017

26. Reply

Author

Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, de Leeuw PW, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, and Williams B

Published
2017

27. Strategies for improving blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. 2012 Position paper of the Italian Society of Hypertension

Author

Volpe M, AMBROSIONI, ETTORE, BORGHI, CLAUDIO, Cottone S, Cuspidi C, De Luca N, Fallo F, Ferri C, Morganti A, Muiesan ML, Sarzani R, Sechi L, Virdis A, Tocci G, Agabiti Rosei E, Trimarco B, Filippi A, Mancia G., Volpe, M, Ambrosioni, E, Borghi, C, Cottone, S, Cuspidi, C, DE LUCA, Nicola, Fallo, F, Ferri, C, Morganti, A, Muiesan, Ml, Sarzani, R, Sechi, L, Virdis, A, Tocci, G, Agabiti Rosei, E, Trimarco, Bruno, Filippi, A, Mancia, G., Volpe M, Ambrosioni E, Borghi C, Cottone S, Cuspidi C, De Luca N, Fallo F, Ferri C, Morganti A, Muiesan ML, Sarzani R, Sechi L, Virdis A, Tocci G, Agabiti-Rosei E, Trimarco B, Filippi A, and Mancia G

Subjects
cardiovascular risk, Italy, Cardiovascular Diseases, Hypertension, Humans, ipertensione arteriosa, BLOOD PRESSURE, Combined Modality Therapy, Risk Assessment, combination therapy
Abstract

Observational studies demonstrate that the proportion of treated hypertensive patients who attain the recommended blood pressure goals (140/90 mmHg) does not exceed 30-40%. Conversely, clinical trials have consistently shown that effective blood pressure control within the recommended targets can be achieved in 70-80% of treated hypertensive patients with different cardiovascular risk profile, especially when appropriate, effective and well tolerated combination therapies are used. In order to bridge the gap between current and optimal blood pressure control rates and to achieve a more effective cardiovascular prevention, the Italian Society of Hypertension has recently developed an interventional strategy that aims to approximate 70% of treated controlled patients by 2015. This ambitious goal can be realistically achieved by the appropriate use of modern aids and tools, also including the implementation of combination therapy, especially if this approach can be simplified into a single pill, now available in Italy. At present, 70-80% of hypertensive patients require combination therapies based on at least two classes of antihypertensive drugs to achieve the recommended blood pressure goals. It is therefore of paramount importance to implement this strategy in routine clinical practice. Among the different combination therapies, the use of combination strategies based on drugs inhibiting the renin-angiotensin system, such as angiotensin receptor blockers and angiotensin-converting enzyme inhibitors, combined with diuretics and/or calcium-channel blockers, have demonstrated to significantly reduce the rates of major cardiovascular events and discontinuations from prescribed therapies, resulting in higher antihypertensive efficacy and better tolerability than monotherapy. The present document of the Italian Society of Hypertension aims to provide main indications for implementing combination therapy in the clinical management of hypertension in order to improve blood pressure control in Italy.

Published
2012

29. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome

Author

Van Bortel, L, Boutouyrie, P, Laurent, S, Pannier, B, Zannad, F, Schmieder, R, Agabiti Rosei, E, Stehouwer, C, Cockcroft, J, Wilkinson, I., GIANNATTASIO, CRISTINA, MANCIA, GIUSEPPE, Van Bortel, L, Boutouyrie, P, Laurent, S, Pannier, B, Zannad, F, Schmieder, R, Agabiti Rosei, E, Giannattasio, C, Mancia, G, Stehouwer, C, Cockcroft, J, Wilkinson, I, MUMC+: HVC Pieken Maastricht Studie (9), Interne Geneeskunde, MUMC+: MA Interne Geneeskunde (3), and RS: CARIM - R3 - Vascular biology

Subjects
medicine.medical_specialty, hypertension, Carotid arteries, compliance, arteries, Internal medicine, medicine.artery, Internal Medicine, medicine, Pulse wave velocity, Aorta, business.industry, blood pressure, arterie, antihypertensive agents, medicine.disease, Compliance (physiology), aorta, Blood pressure, Endocrinology, randomized controlled trial, Cardiology, antihypertensive agent, Aortic stiffness, Metabolic syndrome, business, Olmesartan, medicine.drug
Abstract

Whether angiotensin receptor blockers can dose-dependently remodel the arterial wall during long-term treatment has been largely debated. In this phase III, multicenter, randomized, double-blind, parallel-group study, 133 subjects with hypertension and metabolic syndrome were assigned to olmesartan, either 20 mg (n=44), 40 mg (n=42), or 80 mg (n=47) once a day, according to a force titration design during a 1-year period. Office blood pressure, 24-hour blood pressure, aortic stiffness (carotid-femoral pulse wave velocity), and carotid parameters were measured at baseline, 24 weeks, and 52 weeks. Pulse wave velocity significantly decreased ( P P =0.0685) for a smaller effect of 20 mg, compared with 40 and 80 mg at week 52. When the 40 and 80 mg doses were combined (40/80 mg versus 20 mg), a significant blood pressure–independent reduction in pulse wave velocity (−0.61 m/s) was observed at week 52 ( P =0.0066), whereas the nonadjusted reduction was −1.31 m/s ( P

Published
2014

32. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

Author

Trimarco, THE TELMISARTAN RANDOMISED ASSESSMENT STUDY IN ACE INTOLERANT SUBJECTS WITH CARDIOVASCULAR DISEASE TRANSCEND INVESTIGATORS Italy: B., Verdecchia, P., Maggioni, A., Achilli, A., Agabiti Rosei, E., Ambrosio, Gb, Bentivoglio, M., Branzi, A., Chersevani, D., Chiariello, M., Cirrincione, V., Dembech, C., Ferrari, R., Gattobigio, R., Giovannini, E., Lauro, R., Lembo, Giuseppe, Moretti, L., Pancaldi, L., Pede, S., Pettinati, G., Reboldi, G., Ricci, R., Rosiello, G., Rozza, F., Sardone, Mg, Tavazzi, L., Terrosu, P., Venco, A., Vetrano, A., and Volpe, Massimo

Subjects
Male, medicine.medical_specialty, Angiotensin-Converting Enzyme Inhibitors, Kaplan-Meier Estimate, Klinikai orvostudományok, Placebo, Benzoates, law.invention, Randomized controlled trial, law, Internal medicine, medicine, Humans, Single-Blind Method, Telmisartan, Myocardial infarction, Angioedema, Stroke, Aged, Intention-to-treat analysis, biology, business.industry, Angiotensin-converting enzyme, Orvostudományok, General Medicine, medicine.disease, ACE inibitori, AT1 bloccanti, trial clinico, Candesartan, Cough, Therapeutic Equivalency, Cardiovascular Diseases, Anesthesia, biology.protein, Benzimidazoles, Female, Hypotension, business, Risk Reduction Behavior, Follow-Up Studies, medicine.drug
Abstract

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors reduce major cardiovascular events, but are not tolerated by about 20% of patients. We therefore assessed whether the angiotensin-receptor blocker telmisartan would be effective in patients intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ damage. METHODS: After a 3-week run-in period, 5926 patients, many of whom were receiving concomitant proven therapies, were randomised to receive telmisartan 80 mg/day (n=2954) or placebo (n=2972) by use of a central automated randomisation system. Randomisation was stratified by hospital. The primary outcome was the composite of cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00153101. FINDINGS: The median duration of follow-up was 56 (IQR 51-64) months. All randomised patients were included in the efficacy analyses. Mean blood pressure was lower in the telmisartan group than in the placebo group throughout the study (weighted mean difference between groups 4.0/2.2 [SD 19.6/12.0] mm Hg). 465 (15.7%) patients experienced the primary outcome in the telmisartan group compared with 504 (17.0%) in the placebo group (hazard ratio 0.92, 95% CI 0.81-1.05, p=0.216). One of the secondary outcomes-a composite of cardiovascular death, myocardial infarction, or stroke-occurred in 384 (13.0%) patients on telmisartan compared with 440 (14.8%) on placebo (0.87, 0.76-1.00, p=0.048 unadjusted; p=0.068 after adjustment for multiplicity of comparisons and overlap with primary outcome). 894 (30.3%) patients receiving telmisartan were hospitalised for a cardiovascular reason, compared with 980 (33.0%) on placebo (relative risk 0.92, 95% CI 0.85-0.99; p=0.025). Fewer patients permanently discontinued study medication in the telmisartan group than in the placebo group (639 [21.6%] vs 705 [23.8%]; p=0.055); the most common reason for permanent discontinuation was hypotensive symptoms (29 [0.98%] in the telmisartan group vs 16 [0.54%] in the placebo group). INTERPRETATION: Telmisartan was well tolerated in patients unable to tolerate ACE inhibitors. Although the drug had no significant effect on the primary outcome of this study, which included hospitalisations for heart failure, it modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction, or stroke. FUNDING: Boehringer Ingelheim.

Published
2008

34. P464Clinic and 24 hours blood pressure values are strictly related to dimensions of the ascending aorta in a general population

Author

Salvetti, M., primary, Paini, A., additional, Bertacchini, F., additional, Stassaldi, D., additional, Agabiti Rosei, C., additional, Aggiusti, C.Q., additional, Maruelli, G., additional, Rubagotti, G., additional, Verzeri, L., additional, Sacca', G., additional, Agabiti-Rosei, E., additional, and Muiesan, M.L., additional

Published
2017
Full Text
View/download PDF

35. P141 COMPARISON BETWEEN TECHNIQUES OF EVALUATION MICROVASCULAR MORPHOLOGY: THE GOLD-STANDARD LOCALLY INVASIVE MICROMYOGRAPHY VS. THREE NON-INVASIVE TECHNIQUES. PRELIMINARY DATA

Author

De Ciuceis, C., primary, Caletti, S., primary, Coschignano, M.A., primary, Rossini, C., primary, Duse, S., primary, Docchio, F., primary, Pasinetti, S., primary, Zambonardi, F., primary, Semeraro, F., primary, Sansoni, G., primary, Agabiti Rosei, C., primary, Pileri, P., primary, Agabiti Rosei, E., primary, and Rizzoni, D., primary

Published
2017
Full Text
View/download PDF

37. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008

Author

Danaei, G., Singh, G., Paciorek, C., Lin, J., Cowan, M., Finucane, M., Farzadfar, F., Stevens, G., Riley, L., Lu, Y., Rao, M., Ezzati, M., Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group, Aamodt, G., Abdeen, Z., Abdella, N., Rahim, H., Addo, J., Aekplakorn, W., Afifi, M., Agabiti Rosei, E., Aguilar Salinas CA, Agyemang, C., Ali, M., Al Nsour, M., Al Nuaim AR, Ambady, R., Aro, P., Azizi, F., Barbagallo, C., Barbieri, M., Barceló, A., Barreto, S., Barros, H., Bautista, L., Benetos, A., Bjerregaard, P., Björkelund, C., Bo, S., Bobak, M., Bonora, E., Bontha, B., Botana, M., Bovet, P., Breckenkamp, J., Breteler, M., Broda, G., Brown, I., Bursztyn, M., Cabrera de León, A., Campos, H., Cappuccio, F., Capuano, V., Casiglia, E., Castellano, M., Castetbon, K., Cea, L., Chang, C., Chaouki, N., Chatterji, S., Chen, Z., Chen, C., Choi, J., Chua, L., Cífková, R., Cobiac, L., Cooper, R., Corsi, A., Costanza, M., Craig, C., Dankner, R., Dastgiri, S., Delgado, E., Dinc, G., Doi, Y., Dong, G., Dorsi, E., Dragano, N., Drewnowski, A., Eggertsen, W., Elliott, P., Engeland, A., Erem, C., Esteghamati, A., Fall, C., Fan, J., Ferreccio, C., Fezeu, L., Firmo, J., Florez, H., Fornés, N., Fowkes, F., Franceschini, G., Frisk, F., Fuchs, F., Fuller, E., Getz, L., Giampaoli, S., Gómez, L., Gomez Zumaquero JM, Graff Iversen, S., Grant, J., Guerrero Carvajal, R., Gulliford, M., Gupta, R., Gupta, P., Gureje, O., Hansen, T., Hata, J., He, J., Heim, N., Heinrich, J., Hemmingsson, T., Hennis, A., Herman, W., Herrera, V., Ho, S., Holdsworth, M., Hollman Frisman, G., Hopman, W., Hussain, A., Husseini, A., Ibrahim, M., Ikeda, N., Jacobsen, B., Jaddou, H., Jafar, T., Janghorbani, M., Jasienska, G., Joffres, M., Jonas, J., Kadiki, O., Kalter Leibovici, O., Kamadjeu, R., Karalis, I., Kastarinen, M., Katz, J., Keinan Boker, L., Kelly, P., Khalilzadeh, O., Khang, Y., Kiechl, S., Kim, K., Kiyohara, Y., Kobayashi, J., Krause, M., Kubínová, R., Kurjata, P., Kusuma, Y., Lam, T., Langhammer, A., Lawes, C., Le, C., Lee, J., Lévy Marchal, C., Li, Y., Lim, S., Lim, T., Lin, X., Lin, C., Lin, H., Lind, L., Lissner, L., Liu, X., Lopez Jaramillo, P., Lorbeer, R., Ma, G., Ma, S., Macià, F., Maclean, D., Maggi, S., Magliano, D., Makdisse, M., Mancia, G., Mannami, T., Marques Vidal, P., Mbanya, J., McFarlane Anderson, N., Miccoli, R., Miettola, J., Minh, H., Miquel, J., Miranda, J., Mohamed, M., Mohan, V., Mohanna, S., Mokdad, A., Mollentze, W., Morales, D., Morgan, K., Muiesan, L., Muntoni, S., Nabipour, I., Nakagami, T., Nangia, V., Nemesure, B., Neovius, M., Nerhus, K., Nervi, F., Neuhauser, H., Nguyen, M., Ninomiya, T., Noale, M., Oh, S., Ohkubo, T., Olivieri, O., Önal, A., Onat, A., Oróstegui, M., Ouedraogo, H., Pan, W., Panagiotakos, D., Panza, F., Park, Y., Passos, V., Pednekar, M., Peres, M., Pérez, C., Pérez Fernández, R., Pichardo, R., Phua, H., Pistelli, F., Plans, P., Polakowska, M., Poulter, N., Prabhakaran, D., Qiao, Q., Rafiei, M., Raitakari, O., Ramos, L., Rampal, S., Rampal, L., Rasmussen, F., Reddy, K., Redon, J., Revilla, L., Reyes García, V., Roaeid, R., Rodriguez Artalejo, F., Rojas Martinez, R., Ronkainen, K., Rosero Bixby, L., Roth, G., Sachdev, H., Sánchez, J., Sanisoglu, S., Sans, S., Sarraf Zadegan, N., Scazufca, M., Schaan, B., Schapochnik, N., Schelleman, H., Schneider, I., Schooling, C., Schwarz, B., Sekuri, C., Sereday, M., Serra Majem, L., Shaw, J., Shera, A., Shi, Z., Shiri, R., Shu, X., Silva, D., Silva, E., Simons, L., Smith, M., Söderberg, S., Soebardi, S., Solfrizzi, V., Sonestedt, E., Soysal, A., Stattin, P., Stein, A., Stergiou, G., Stessman, J., Sudo, A., Suka, M., Sundh, V., Sundquist, K., Sundström, J., Swai, A., Tai, E., Tambs, K., Tesfaye, F., Thomas, G., Thorogood, M., Tilvis, R., Tobias, M., Torheim, L., Trenkwalder, P., Tuomilehto, J., Tur, J., Tzourio, C., Uhernik, A., Ukoli, F., Unwin, N., Vander Hoorn, S., Vanderpump, M., Varo, J., Veierød, B., Velásquez Meléndez, G., Verschuren, M., Viet, L., Villalpando, S., Vioque, J., Vollenweider, P., Volpato, S., Wang, N., Wang, Y., Ward, M., Waspadji, S., Welin, L., Wilhelmsen, L., Willeit, J., Woodward, M., Xavier, A., Xu, F., Xu, L., Yamamoto, A., Yang, G., Yang, X., Yeh, L., Yoon, J., You, Q., Yu, Z., Zhang, J., Zhang, L., Zheng, W., Zhou, M., Danaei G, Singh GM, Paciorek CJ, Lin JK, Cowan MJ, Finucane MM, Farzadfar F, Stevens GA, Riley LM, Lu Y, Rao M, Ezzati M and Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group, Aamodt G, Abdeen Z, Abdella NA, Rahim HF, Addo J, Aekplakorn W, Afifi MM, Agabiti-Rosei E, Aguilar Salinas CA, Agyemang C, Ali MM, Al-Nsour M, Al-Nuaim AR, Ambady R, Aro P, Azizi F, Barbagallo CM, Barbieri MA, Barceló A, Barreto SM, Barros H, Bautista LE, Benetos A, Bjerregaard P, Björkelund C, Bo S, Bobak M, Bonora E, Bontha BV, Botana MA, Bovet P, Breckenkamp J, Breteler MM, Broda G, Brown IJ, Bursztyn M, Cabrera de León A, Campos H, Cappuccio FP, Capuano V, Casiglia E, Castellano M, Castetbon K, Cea L, Chang CJ, Chaouki N, Chatterji S, Chen Z, Chen CJ, Choi JS, Chua L, Cífková R, Cobiac LJ, Cooper RS, Corsi AM, Costanza MC, Craig CL, Dankner RS, Dastgiri S, Delgado E, Dinc G, Doi Y, Dong GH, Dorsi E, Dragano N, Drewnowski A, Eggertsen W, Elliott P, Engeland A, Erem C, Esteghamati A, Fall CH, Fan JG, Ferreccio C, Fezeu L, Firmo JO, Florez HJ, Fornés NS, Fowkes FG, Franceschini G, Frisk F, Fuchs FD, Fuller EL, Getz L, Giampaoli S, Gómez LF, Gomez-Zumaquero JM, Graff-Iversen S, Grant JF, Guerrero Carvajal R, Gulliford MC, Gupta R, Gupta PC, Gureje O, Hansen TW, Hata J, He J, Heim N, Heinrich J, Hemmingsson T, Hennis A, Herman WH, Herrera VM, Ho S, Holdsworth M, Hollman Frisman G, Hopman WM, Hussain A, Husseini A, Ibrahim M, Ikeda N, Jacobsen BK, Jaddou HY, Jafar TH, Janghorbani M, Jasienska G, Joffres MR, Jonas JB, Kadiki OA, Kalter-Leibovici O, Kamadjeu RM, Karalis I, Kastarinen MJ, Katz J, Keinan-Boker L, Kelly P, Khalilzadeh O, Khang YH, Kiechl S, Kim KW, Kiyohara Y, Kobayashi J, Krause MP, Kubínová R, Kurjata P, Kusuma YS, Lam TH, Langhammer A, Lawes CM, Le C, Lee J, Lévy-Marchal C, Li Y, Lim S, Lim TO, Lin X, Lin CC, Lin HH, Lind L, Lissner L, Liu X, Lopez-Jaramillo P, Lorbeer R, Ma G, Ma S, Macià F, MacLean DR, Maggi S, Magliano DJ, Makdisse M, Mancia G, Mannami T, Marques-Vidal P, Mbanya JC, McFarlane-Anderson N, Miccoli R, Miettola J, Minh HV, Miquel JF, Miranda J, Mohamed MK, Mohan V, Mohanna S, Mokdad A, Mollentze WF, Morales DD, Morgan K, Muiesan LM, Muntoni S, Nabipour I, Nakagami T, Nangia V, Nemesure B, Neovius M, Nerhus KA, Nervi F, Neuhauser H, Nguyen M, Ninomiya T, Noale M, Oh SW, Ohkubo T, Olivieri O, Önal AE, Onat A, Oróstegui M, Ouedraogo H, Pan WH, Panagiotakos DB, Panza F, Park Y, Passos VM, Pednekar MS, Peres MA, Pérez C, Pérez-Fernández R, Pichardo R, Phua HP, Pistelli F, Plans P, Polakowska M, Poulter N, Prabhakaran D, Qiao Q, Rafiei M, Raitakari OT, Ramos LR, Rampal S, Rampal L, Rasmussen F, Reddy KK, Redon J, Revilla L, Reyes-García V, Roaeid RB, Rodriguez-Artalejo F, Rojas-Martinez R, Ronkainen K, Rosero-Bixby L, Roth GA, Sachdev HS, Sánchez JR, Sanisoglu SY, Sans S, Sarraf-Zadegan N, Scazufca M, Schaan BD, Schapochnik N, Schelleman H, Schneider IJ, Schooling C, Schwarz B, Sekuri C, Sereday MS, Serra-Majem L, Shaw J, Shera AS, Shi Z, Shiri R, Shu XO, Silva DA, Silva E, Simons LA, Smith M, Söderberg S, Soebardi S, Solfrizzi V, Sonestedt E, Soysal A, Stattin P, Stein AD, Stergiou GS, Stessman J, Sudo A, Suka M, Sundh V, Sundquist K, Sundström J, Swai AB, Tai E, Tambs K, Tesfaye F, Thomas GN, Thorogood M, Tilvis RS, Tobias M, Torheim LE, Trenkwalder P, Tuomilehto JO, Tur JA, Tzourio C, Uhernik AI, Ukoli FA, Unwin N, Vander Hoorn S, Vanderpump MP, Varo JJ, Veierød B, Velásquez-Meléndez G, Verschuren M, Viet L, Villalpando S, Vioque J, Vollenweider P, Volpato S, Wang N, Wang YX, Ward M, Waspadji S, Welin LX, Wilhelmsen L, Willeit J, Woodward M, Xavier AJ, Xu F, Xu L, Yamamoto A, Yang G, Yang X, Yeh LC, Yoon JS, You Q, Yu Z, Zhang J, Zhang L, Zheng W, Zhou M, ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, and Public and occupational health

Subjects
Gerontology, Adult, Male, Risk, medicine.medical_specialty, Settore MED/09 - Medicina Interna, Measures of national income and output, Population, Hypercholesterolemia, OBESIDADE, Blood Pressure, Global Health, Body Mass Index, Age Distribution, Risk Factors, cardiovascular disease, Physiology (medical), Diabetes mellitus, risk factors, Epidemiology, medicine, Diabetes Mellitus, Humans, Obesity, Risk factor, Sex Distribution, education, Developing Countries, Cholesterolo, education.field_of_study, business.industry, Urbanization, Feeding Behavior, Middle Aged, medicine.disease, Blood pressure, Cholesterol, Socioeconomic Factors, Cardiovascular Diseases, Hypertension, Western World, Female, Cardiology and Cardiovascular Medicine, business, Body mass index, Demography
Abstract

Background— It is commonly assumed that cardiovascular disease risk factors are associated with affluence and Westernization. We investigated the associations of body mass index (BMI), fasting plasma glucose, systolic blood pressure, and serum total cholesterol with national income, Western diet, and, for BMI, urbanization in 1980 and 2008. Methods and Results— Country-level risk factor estimates for 199 countries between 1980 and 2008 were from a previous systematic analysis of population-based data. We analyzed the associations between risk factors and per capita national income, a measure of Western diet, and, for BMI, the percentage of the population living in urban areas. In 1980, there was a positive association between national income and population mean BMI, systolic blood pressure, and total cholesterol. By 2008, the slope of the association between national income and systolic blood pressure became negative for women and zero for men. Total cholesterol was associated with national income and Western diet in both 1980 and 2008. In 1980, BMI rose with national income and then flattened at ≈Int$7000; by 2008, the relationship resembled an inverted U for women, peaking at middle-income levels. BMI had a positive relationship with the percentage of urban population in both 1980 and 2008. Fasting plasma glucose had weaker associations with these country macro characteristics, but it was positively associated with BMI. Conclusions— The changing associations of metabolic risk factors with macroeconomic variables indicate that there will be a global pandemic of hyperglycemia and diabetes mellitus, together with high blood pressure in low-income countries, unless effective lifestyle and pharmacological interventions are implemented.

Published
2013

38. [Renal denervation for the treatment of resistant hypertension: definition, patient selection and description of the procedure. 2012 Position paper of the Italian Society of Hypertension]

Author

Volpe, M, Agabiti Rosei, E, Ambrosioni, E, Cottone, S, Borghi, C, De Luca, N, Fallo, F, Ferri, C, Muiesan, M, Sarzani, R, Sechi, L, Tocci, G, Virdis, A., CUSPIDI, CESARE, MANCIA, GIUSEPPE, MORGANTI, ALESSANDRO, Volpe, M, Agabiti Rosei, E, Ambrosioni, E, Cottone, S, Cuspidi, C, Borghi, C, DE LUCA, Nicola, Fallo, F, Ferri, C, Mancia, G, Morganti, A, Muiesan, Ml, Sarzani, R, Sechi, L, Tocci, G, Virdis, A., De Luca, N, Muiesan, M, and Virdis, A

Subjects
Patient Selection, Hypertension, Humans, ipertensione arteriosa, Kidney, [Renal denervation, resistant hypertension, Denervation
Abstract

Hypertension is responsible for a relevant burden of cardiovascular morbidity and mortality worldwide. Although several appropriate and integrated pharmacological strategies are available, blood pressure control still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on overall cardiovascular risk, since it significantly increases the risk of both macrovascular and microvascular complications. Hypertension is arbitrarily defined as "resistant" or "refractory" when recommended blood pressure goals (clinic blood pressure

Published
2012

39. Outcomes of Patients Hospitalized with Community-Acquired, Health Care-Associated, and Hospital-Acquired Pneumonia

Author

Venditti, M, Falcone, M, Corrao,S, Licata, G, Serra, P, Study Group of the Italian Society of Internal Medicine, Salerno, F, Filetti, S, D’Erasmo, E, Rossi Fanelli, F, Cricco, L, Gasbarrone, L, Serafini, C, Ghio, R, Zoppoli, G, Cortellaro, M, Magenta, M, Nuti, R, Valenti, R, Milano, V, Brandimarte, C, Carfagna, P, Di Sciacca, R, Tuttolomondo, A, Serra, MG, Bernardi, M, Li Bassi, S, Stanghellini, V, Boschi, E, Antonaci, S, Vella, F, Catalano, A, Zeneroli, ML, Ascari, E, Veggetti, A, Manfredini, R, Gamberoni, S, Guarnieri, G, Fioretto, A, Di Michele, D, Parisi, D, Liberato, NL, Ronchi, E, Sturbini, S, Canafoglia, P, Gallerani, M, Boari, B, Nielsen, I, Rossetti, A, Bernasconi, M, Giannatempo, C, Turconi, R, Colombo, M, Cappelli, R. Guidi, V, Tassara, R, De Melis, D, Cosentini, R, Arioli, M, Gobbo, G, Presotto, F, Gallana, S, Balduini, C, Bertolino, G, Fera, G, Corazza, RG, Capriglione, I, Pilerio, G, Cappellini, MD, Fabio, G, Carrabba, M, Wu, SC, Secchi, MB, Leone, M, De Feudis, L, Gunelli, M, Ferri, O, Doroldi, C, Pistis, R, Sabbadini, MG, Tresoldi, M, Tedeschi, A, Rossio, R, Lambelet, P, Fascetti, S, Vanoli, M, Casella, G, Agabiti Rosei, E, Salvi, A, Noto, A, Perciaccante, A, Santini, C, Galie`, M, Gasbarrini, G, Grieco, A, Nardi, B, Baritussio, AG, Vannuccini, R, Cappelletti, M, Gentiloni Silveri, N, Lechi, A, Montesi, G., ANNONI, GIORGIO, Venditti, M, Falcone, M, Corrao, S, Licata, G, Serra, P, Study Group of the Italian Society of Internal, M, Salerno, F, Filetti, S, D’Erasmo, E, Rossi Fanelli, F, Cricco, L, Gasbarrone, L, Serafini, C, Ghio, R, Zoppoli, G, Cortellaro, M, Magenta, M, Nuti, R, Valenti, R, Milano, V, Brandimarte, C, Carfagna, P, Di Sciacca, R, Tuttolomondo, A, Serra, M, Bernardi, M, Li Bassi, S, Stanghellini, V, Boschi, E, Antonaci, S, Vella, F, Catalano, A, Zeneroli, M, Ascari, E, Veggetti, A, Manfredini, R, Gamberoni, S, Guarnieri, G, Fioretto, A, Di Michele, D, Parisi, D, Liberato, N, Ronchi, E, Sturbini, S, Canafoglia, P, Gallerani, M, Boari, B, Nielsen, I, Annoni, G, Rossetti, A, Bernasconi, M, Giannatempo, C, Turconi, R, Colombo, M, Cappelli, R., G, V, Tassara, R, De Melis, D, Cosentini, R, Arioli, M, Gobbo, G, Presotto, F, Gallana, S, Balduini, C, Bertolino, G, Fera, G, Corazza, R, Capriglione, I, Pilerio, G, Cappellini, M, Fabio, G, Carrabba, M, Wu, S, Secchi, M, Leone, M, De Feudis, L, Gunelli, M, Ferri, O, Doroldi, C, Pistis, R, Sabbadini, M, Tresoldi, M, Tedeschi, A, Rossio, R, Lambelet, P, Fascetti, S, Vanoli, M, Casella, G, Agabiti Rosei, E, Salvi, A, Noto, A, Perciaccante, A, Santini, C, Galie`, M, Gasbarrini, G, Grieco, A, Nardi, B, Baritussio, A, Vannuccini, R, Cappelletti, M, Gentiloni Silveri, N, Lechi, A, and Montesi, G

Subjects
MED/09 - MEDICINA INTERNA, Acquired Pneumonia, Patients outcomes
Abstract

Background: Traditionally, pneumonia has been classified as either community- or hospital-acquired. Although only limited data are available, health care–associated pneumonia has been recently proposed as a new category of respiratory infection. “Health care–associated pneumonia” refers to pneumonia in patients who have recently been hospitalized, had hemodialysis, or received intravenous chemotherapy or reside in a nursing home or long-term care facility. Objective: To ascertain the epidemiology and outcome of community-acquired, health care–associated, and hospital-acquired pneumonia in adults hospitalized in internal medicine wards. Design: Multicenter, prospective observational study. Setting: 55 hospitals in Italy comprising 1941 beds. Patients: 362 patients hospitalized with pneumonia during two 1-week surveillance periods. Measurements: Cases of radiologically and clinically assessed pneumonia were classified as community-acquired, health care–associated, or hospital-acquired and rates were compared. Results: Of the 362 patients, 61.6% had community-acquired pneumonia, 24.9% had health care–associated pneumonia, and 13.5% had hospital-acquired pneumonia. Patients with health care–associated pneumonia had higher mean Sequential Organ Failure Assessment scores than did those with community-acquired pneumonia (3.0 vs. 2.0), were more frequently malnourished (11.1% vs. 4.5%, and had more frequent bilateral (34.4% vs. 19.7%) and multilobar (27.8% vs. 21.5%) involvement on a chest radiograph. Patients with health care–associated pneumonia also had higher fatality rates (17.8% [CI, 10.6% to 24.9%] vs. 6.7% [CI, 2.9% to 10.5%]) and longer mean hospital stay (18.7 days [CI, 15.9 to 21.5 days] vs. 14.7 days [CI, 13.4 to 15.9 days]). Logistic regression analysis revealed that depression of consciousness (odds ratio [OR], 3.2 [CI, 1.06 to 9.8]), leukopenia (OR, 6.2 [CI, 1.01 to 37.6]), and receipt of empirical antibiotic therapy not recommended by international guidelines (OR, 6.4 [CI, 2.3 to 17.6]) were independently associated with increased intrahospital mortality. Limitations: The number of patients with health care–associated pneumonia was relatively small. Microbiological investigations were not always homogeneous. The study included only patients with pneumonia that required hospitalization; results may not apply to patients treated as outpatients. Conclusion: Health care–associated pneumonia should be considered a distinct subset of pneumonia associated with more severe disease, longer hospital stay, and higher mortality rates. Physicians should differentiate between patients with health care–associated pneumonia and those with community-acquired pneumonia and provide more appropriate initial antibiotic therapy.

Published
2009

40. Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients

Author

Agabiti-Rosei, E. Manolis, A. Zava, D. Omboni, S.

Abstract

Introduction: In most treated patients with hypertension, a two or more drug combination is required to achieve adequate blood pressure (BP) control. In our study we assessed whether the combination of zofenopril + hydrochlorothiazide (HCTZ) was at least as effective as irbesartan + HCTZ in essential hypertensives with at least one additional cardiovascular risk factor, uncontrolled by a previous monotherapy. Methods: After a 2-week placebo washout, 361 treated hypertensive patients [office sitting diastolic BP (DBP), ≥90 mmHg], aged 18-75 years, were randomized double blind to 18-week treatment with zofenopril 30 mg plus HCTZ 12.5 mg or irbesartan 150 mg plus HCTZ 12.5 mg once daily, in an international, multicenter study. After the first 6 and 12 weeks, zofenopril and irbesartan doses could be doubled in non-normalized subjects. The primary study end point was the office sitting DBP reduction after 18 weeks of treatment. Secondary end points included office systolic BP (SBP), ambulatory BP and high sensitivity C-reactive protein (hs-CRP). Results: The between-treatment difference for office DBP averaged to +1.0 (95% CI -0.4, +0.8) mmHg (P = 0.150), the upper limit of the 95% confidence interval being inferior to the protocol-defined non-inferiority limit (3 mmHg). In the subset of patients with valid ambulatory BP, no difference in 24-h average DBP [n = 181; 6.7 (8.7, 4.6) zofenopril + HCTZ vs. 6.3 (8.8, 3.7) mmHg irbesartan + HCTZ, P = 0.810] and SBP reductions [11.7 (15.4, 8.0) vs. 12.6 (17.2, 8.0) mmHg, P = 0.758] were observed between the two treatment groups. hs-CRP was reduced by zofenopril + HCTZ [-0.52 (-1.05, 0.01) mg/L], while it was increased by irbesartan plus HCTZ [0.97 (0.29, 1.65) mg/L, P = 0.001 between treatments]. Conclusion: In previouslymonotherapy-treated, uncontrolled patients with hypertension, zofenopril 30-60mg + HCTZ 12.5 mg is as effective as irbesartan 150-300 mg plus HCTZ 12.5 mg, with the added value of a potential protective effect against vascular inflammation. © The Author(s) 2014.

Published
2014

41. Prevalence of type 2 diabetes among patients withhypertension under the care of 30 Italian clinics ofhypertension: results of the (Iper)tensione and(dia)bete study

Author

Abate G., Agabiti Rosei E., Ambrosio G.B., Ambrosioni E., Cavatorta A., Cerasola G., Cereda U.G., De Divitiis O., Ferrari A., Lechi A., Leonetti G., Martines C., Nami R., Pagani M., Palatini P., Pasotti C., Pirrelli A., Portaluppi F., Rappelli A., Salvetti A., Santucci A., Vanuzzo D., Veglio F., Venco A., Volpe M., BELLINI, GIUSEPPE, Abate, G., Agabiti Rosei, E., Ambrosio, G. B., Ambrosioni, E., Bellini, Giuseppe, Cavatorta, A., Cerasola, G., Cereda, U. G., De Divitiis, O., Ferrari, A., Lechi, A., Leonetti, G., Martines, C., Nami, R., Pagani, M., Palatini, P., Pasotti, C., Pirrelli, A., Portaluppi, F., Rappelli, A., Salvetti, A., Santucci, A., Vanuzzo, D., Veglio, F., Venco, A., and Volpe, M.

Subjects
hypertension, diabetes, diabete, prevalence
Abstract

Background and purpose Hypertension is known to be highly prevalent among patients with diabetes and associated with an increased risk of cardiovascular damage. In contrast, relatively few investigations have addressed the prevalence of diabetes among patients with hypertension. The purpose of the present study was to examine the prevalence of type 2 diabetes, the effectiveness of hypertension and diabetes control and the association with other cardiovascular risk factors and previous cardiovascular diseases in a cohort of patients with hypertension referred to 30 hospital outpatient clinics for the treatment of hypertension. Methods and patients Patients were considered as having diabetes if they were already on an antidiabetic treatment either with diet or medications. All other patients had fasting plasma glucose measured on two separate occasions and were classified as having diabetes if both values were at least 140 mg/dl (7.8 mmol/l) and as not having diabetes if both values were less than 110 mg/dl (6.1 mmol/l). In patients with a single determination of at least 110 mg/dl, the final diagnosis of diabetes was established according to the result of an oral glucose tolerance test. A secondary definition of diabetes was also used, that is two fasting plasma glucose values of at least 126 mg/dl (7.0 mmol/l). In all patients, serum total, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, fasting serum triglycerides, serum creatinine and urinary albumin were also evaluated. Results and conclusion Among the 1397 recruited patients, 242 (17.3%) were diagnosed as having diabetes according to the primary definition and 244 (17.5%) according to the secondary definition. In 195 out of the 242 (14%), the diagnosis was already known whereas, in the remaining 47 (3.3%), it was made de novo. In 61.4% of those already having diabetes, plasma glucose was at least 140 mg/dl (7.8 mmol/l), whereas only in 8.4% of them was it less than 110 mg/dl (6.1 mmol/l). Patients with diabetes were older, heavier and with a greater familiar predisposition. Patients with diabetes had higher values of systolic blood pressure than individuals without diabetes (150W17 vs. 144W16mmHg, respectively; P

Published
2008

42. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma

Author

Rossi, Gp, Belfiore, A, Bernini, Giampaolo, Desideri, G, Fabris, B, Ferri, C, Giacchetti, G, Letizia, C, Maccario, M, Mallamaci, F, Mannelli, M, Palombo, G, Rizzoni, D, Rossi, E, AGABITI ROSEI, E, Pessina, Ac, Mantero, F, FOR THE PAPY STUDY INVESTIGATORS, Rossi, G. P., Belfiore, A., Bernini, G., Desideri, G., Fabris, Bruno, Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mallamaci, F., Mannelli, M., Palumbo, G., Rizzoni, D., Rossi, E., Agabiti Rosei, E., Pessina, A. C., Mantero, F., and Primary Aldosteronism Prevalence In Italy Study, Investigators

Subjects
Male, Captopril, diagnosis, secondary hypertension, aldosterone, aldosteronism, clinical science, secondary, Secondary hypertension, Primary hyperaldosteronism, multiple tests, Sodium Chloride, chemistry.chemical_compound, Primary aldosteronism, Analysis of Variance Captopril/diagnostic use, Prospective Studies, Infusions, Intravenous, Aldosterone, Adrenocortical Adenoma, Captopril challenge test, Female, Intravenous, Adrenocortical Adenoma/diagnosis, medicine.drug, Infusions, medicine.medical_specialty, Adenoma, medicine.drug_class, Urology, Sensitivity and Specificity, Diagnosis, Differential, Internal medicine, Hyperaldosteronism, Adrenal Cortex Neoplasms/diagnosis, Diagnosis, Differential, Hyperaldosteronism/diagnosis, Probability, Sodium Chloride/diagnostic use, Internal Medicine, medicine, Humans, Analysis of Variance, business.industry, medicine.disease, Adrenal Cortex Neoplasms, Endocrinology, chemistry, Mineralocorticoid, ACE inhibitor, business
Abstract

We performed a prospective head-to-head comparison of the accuracy of the captopril test (CAPT) and the saline infusion test (SAL) for confirming primary aldosteronism due to an aldosterone-producing adenoma (APA) in patients with different sodium intake. A total of 317 (26.9%) of the 1125 patients screened in the Primary Aldosteronism Prevalence in Italy Study underwent both CAPT and SAL. They were composed of the patients with a high aldosterone/renin ratio baseline and 1 every 4 patients without such criterion. The accuracy of post-CAPT or post-SAL plasma aldosterone values for diagnosing APA was estimated with the area under the receiver operator characteristics curves. Primary aldosteronism was found in 120 patients, of which 46 had an APA. No untoward effect occurred with either test. The area under the receiver operator characteristics curve of plasma aldosterone for both tests was higher ( P P =0.054). The optimal aldosterone cutoff value for identifying APA was 13.9 and 6.75 ng/dL for the CAPT and SAL, respectively. Even at these cutoffs, sensitivity and specificity were moderate because of overlap of values between patients with and without APA. When examined in relation to sodium intake, the accuracy of the SAL surpassed that of the CAPT in the patients with a sodium intake ≤130 mEq per day; this difference waned at a higher Na + intake. Thus, both the CAPT and the SAL are safe and moderately accurate for excluding APA; at a sodium intake >7.6 g per day, the SAL offers no advantage over the easier-to-perform CAPT.

Published
2007

43. 2007 Guidelines for the management of arterial hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Author

MANCIA, GIUSEPPE, GRASSI, GUIDO, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Heagerty, AM, Kjeldsen, SE, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, RE, Struijker Boudier, HAJ, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, SD, McGregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, JL, Erdine, S, Kiowski, W, Agabiti Rosei, E, Ambrosioni, E, Lindholm, LH, Mancia, G, Manolis, A, Nilsson, PM, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, J, Manolis, AJ, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, Williams, B, The task force for the management of arterial hypertension of the European Society of Hypertension, n, The task force for the management of arterial hypertension of the European Society of Cardiology, n., University of Zurich, Mancia, G, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Grassi, G, Heagerty, A, Kjeldsen, S, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, R, Struijker Boudier, H, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, S, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, J, Erdine, S, Kiowski, W, Agabiti Rosei, E, Ambrosioni, E, Lindholm, L, Manolis, A, Nilsson, P, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, J, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, Williams, B, The task force for the management of arterial hypertension of the European Society of Hypertension, N, and The task force for the management of arterial hypertension of the European Society of Cardiology, N

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Alternative medicine, 610 Medicine & health, World health, 2705 Cardiology and Cardiovascular Medicine, Organ damage, Europe, Resource (project management), Family medicine, Medical, Health care, Hypertension, medicine, 10209 Clinic for Cardiology, Diagnostic assessment, Humans, Cardiology and Cardiovascular Medicine, business, Hypertension/classification/diagnosis/therapy, Societies, Societies, Medical, Medical literature
Abstract

For several years the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) decided not to produce their own guidelines on the diagnosis and treatment of hypertension but to endorse the guidelines on hypertension issued by the World Health Organization (WHO) and International Society of Hypertension (ISH)1,2 with some adaptation to reflect the situation in Europe. However, in 2003 the decision was taken to publish ESH/ESC specific guidelines3 based on the fact that, because the WHO/ISH Guidelines address countries widely varying in the extent of their health care and availability of economic resource, they contain diagnostic and therapeutic recommendations that may be not totally appropriate for European countries. In Europe care provisions may often allow a more in-depth diagnostic assessment of cardiovascular risk and organ damage of hypertensive individuals as well as a wider choice of antihypertensive treatment. The 2003 ESH/ESC Guidelines3 were well received by the clinical world and have been the most widely quoted paper in the medical literature in the last two years.4 However, since 2003 considerable additional evidence on important issues related to diagnostic and treatment approaches to hypertension has become available and therefore updating of the previous guidelines has been found advisable. In preparing the new guidelines the Committee established by the ESH and ESC has agreed to adhere to the principles informing the 2003 Guidelines, namely 1) to try to offer the best available and most balanced recommendation to all health care providers involved in the management of hypertension, 2) to address this aim again by an extensive and critical review of the data accompanied by a series of boxes where specific recommendations are given, as well as by a concise set of practice recommendations to be published soon thereafter as already done in 2003; …

Published
2007

44. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma

Author

Rossi, Gp, Belfiore, A, Bernini, G, Desideri, Giovambattista, Fabris, B, Ferri, Claudio, Giacchetti, G, Letizia, C, Maccario, M, Mallamaci, F, Mannelli, M, Montemurro, D, Palumbo, G, Rizzoni, D, Rossi, E, Semplicini, A, AGABITI ROSEI, E, Pessina, Ac, Mantero, F, Papy, Study, Investigators, Rossi, Gp, Belfiore, A, Bernini, G, Desideri, G, Fabris, Bruno, Ferri, C, Giacchetti, G, Letizia, C, Maccario, M, Mallamaci, F, Mannelli, M, Montemurro, D, Palumbo, G, Rizzoni, D, Rossi, E, Semplicini, A, AGABITI ROSEI, E, Pessina, Ac, and Mantero, F.

Subjects
Adenoma, medicine.medical_specialty, Hydrocortisone, Physiology, medicine.drug_class, Urology, Adrenal Gland Neoplasms, Secondary hypertension, Sodium Chloride, Diagnosis, Differential, chemistry.chemical_compound, Primary aldosteronism, Internal medicine, Hyperaldosteronism, Renin, Internal Medicine, Medicine, Humans, Prospective Studies, Prospective cohort study, Infusions, Intravenous, Aldosterone, Aldosteronism, business.industry, Reproducibility of Results, Middle Aged, medicine.disease, Endocrinology, chemistry, ROC Curve, Mineralocorticoid, Hypertension, Differential diagnosis, Cardiology and Cardiovascular Medicine, business
Abstract

BACKGROUND: Data on the performance of the tests used to confirm the diagnosis of primary aldosteronism (PA) are limited. OBJECTIVE: To prospectively investigate the accuracy of the saline infusion test (SIT). METHODS: Three hundred and seventeen (26.9%) out of 1125 patients screened in the PAPY study underwent measurement of plasma aldosterone, cortisol and renin activity after infusion of 2 l of isotonic saline intravenously over 4 h. They comprised patients with a baseline aldosterone/renin ratio (ARR) > 40 and one every four patients not fulfilling such criterion. The area under the receiver-operator characteristic curves (AUC) of aldosterone values after SIT was used as a measure of accuracy for diagnosing PA, aldosterone-producing adenoma (APA) or idiopathic hyperaldosteronism (IHA). RESULTS: One hundred and twenty (37.9%) patients had PA that was due to an APA in 46 (38.3%) and to IHA in 74 (61.7%). No untoward effect occurred with the SIT. The AUC (0.811 ± 0.026, 0.878 ± 0.040 and 0.784 ± 0.034 for identification of PA, APA and IHA, respectively) was higher (P < 0.0001) than that under the diagonal. By sensitivity/specificity versus criterion values plot, the best aldosterone cut-off values for identifying APA and IHA were 6.75 and 6.91 ng/dl, respectively. However, even at these optimal cut-offs, sensitivity and specificity were moderate because of values overlapping between patients with and without the disease. Moreover, there were no differences of AUC and aldosterone cut-offs between APA and IHA. CONCLUSION: In a multicenter study the SIT was safe and specific for excluding PA, but had no place for discriminating between an APA and IHA.

Published
2007

45. Growth hormone secretion in heart failure

Author

Giustina A, Bonadonna S, Burattin A, Filippo Manelli, Lorusso R, Volterrani M, Villa S, Dei Cas L, Agabiti Rosei E, Giustina, Andrea, Bonadonna, S, Burattin, A, Manelli, F, Lorusso, R, Volterrani, M, Villa, S, Dei Cas, L, and Agabiti Rosei, E.

Subjects
Heart Failure, Male, Hypothalamo-Hypophyseal System, Cachexia, Human Growth Hormone, Myocardium, Drug Resistance, Heart, Growth Hormone-Releasing Hormone, Myocardial Contraction, Rats, Vasodilation, Pituitary Gland, Anterior, Growth Hormone, Insulin Secretion, Animals, Humans, Insulin, Insulin-Like Growth Factor I, Secretory Rate
Abstract

Growth hormone is a pituitary polypeptide hormone regulating growth in paediatric age as well as inducing anabolic actions directly or IGF-I mediated in adult age. Particularly, in many animals GH and IGF-I receptors were observed in cardiac myocyte membrane. GH modifies left ventricle structure and function. As concerns spontaneous GH secretion, some data suggest that pituitary gland can have a compensatory role on endocrine response to heart failure. Heart failure stage was directly correlated to nocturnal GH levels. All GH spontaneous night secretion parameters as well as IGF-I levels showed a range between normal people and very high spontaneous secretion. Therefore in these patients there are either a GH peripheric resistance or a reduction of the activity of GH/IGF-I axis. Anyhow in our patients, GH 24 hour infusion was inducing a 5 fold increase in GH concentration and a 50% increase in basal IGF-I levels. Anker et al. suggested to evaluate nutritional state in heart failure patients, observing no differences in non-cachectic patients vs controls, while cachectic patients presented a typical GH resistance syndrome. Interestingly, cardiovascular effects of GH administration seem to be only marginally correlated to hemodynamic basal state. On the other hand basal hormonal setting of the patient seems to correlate to the GH-induced cardiovascular response. In fact, low basal IGF-I but high basal GH patients presented the worst endocrine and cardiovascular response to GH infusion. In literature there are controversial data about GH treatment in patients with chronic heart failure. The heterogeneity of the population could be the reason for this discrepancy. Besides very different IGF-I responses to GH have been reported. Therefore, as there is good clinical evidence that GH acute infusion can improve heart failure, it seems to be necessary firstly to evaluate the basal endocrine status of the patients. Particularly attention should be given to those patients that present a peripheric GH resistance. On the other hand, those patients with a reduced pituitary GH reserve are supposed to have very beneficial effects from GH treatment.

Published
2003

46. Population based strategy for dietary salt intake reduction: Italian initiatives in the European framework

Author

Strazzullo, P, Cairella, G, Campanozzi, A, Carcea, M, Galeone, D, Galletti, F, Giampaoli, S, Iacoviello, L, Siani A, Scalfi L., Simonetti, P, Agabiti Rosei, E, Castellano, M, Fallo, F, Giacchetti, G, Malatino, Lorenzo, Manunta, P, Morganti, A, Rossi, E, Sarzani, R, Veglio, F, Volpe, M, Trimarco, B, Lombardi, G, Mantero, F, Vitti, P, Borghi, L, Nouvenne, A, Mallamaci, F, and Campanozzi, A.

Subjects
cardiovascular risk, hypertension, salt intake
Published
2012

49. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function

Author

Poppe, K.K., primary, Doughty, R.N., additional, Gardin, J.M., additional, Hobbs, F.D.R., additional, McMurray, J.J.V., additional, Nagueh, S.F., additional, Senior, R., additional, Thomas, L., additional, Whalley, G.A., additional, Aune, E., additional, Brown, A., additional, Badano, L.P., additional, Cameron, V., additional, Chadha, D.S., additional, Chahal, N., additional, Chien, K.L., additional, Daimon, M., additional, Dalen, H., additional, Detrano, R., additional, Akif Duzenli, M., additional, Ezekowitz, J., additional, de Simone, G., additional, Di Pasquale, P., additional, Fukuda, S., additional, Gill, P.S., additional, Grossman, E., additional, Kim, H.-K., additional, Kuznetsova, T., additional, Leung, N.K.W., additional, Linhart, A., additional, McDonagh, T.A., additional, McGrady, M., additional, Mill, J.G., additional, Mogelvang, R., additional, Muiesan, M.L., additional, Ng, A.C.T., additional, Ojji, D., additional, Otterstad, J.E., additional, Petrovic, D.J., additional, Poppe, K.K., additional, Prendergast, B., additional, Rietzschel, E., additional, Schirmer, H., additional, Schvartzman, P., additional, Simova, I., additional, Sliwa, K., additional, Stewart, S., additional, Squire, I.B., additional, Takeuchi, M., additional, Altman, D.G., additional, Perera, R., additional, Triggs, C.M., additional, Au Yeung, H., additional, Beans Picón, G.A., additional, Anderson, T., additional, Dyck, J., additional, Ezekowitz, J.A., additional, Chirinos, J.A., additional, De Buyzere, M.L., additional, Gillebert, T.C., additional, Segers, P., additional, Van daele, C.M., additional, Walsh, H.A., additional, Izzo, R., additional, De Luca, N., additional, Trimarco, B., additional, Goel, K., additional, Misra, A., additional, Chen, P.-C., additional, Lin, H.-J., additional, Su, T.-C., additional, Richards, A.M., additional, Troughton, R., additional, Skov Jensen, J., additional, Paterna, S., additional, Davies, M.K., additional, Davis, R.C., additional, Roalfe, A., additional, Calvert, M., additional, Freemantle, N., additional, Lip, G.Y.H., additional, Staessen, J.A., additional, Dargie, H.J., additional, Ford, I., additional, Galasko, G., additional, Lahiri, A., additional, Carrington, M., additional, Krum, H., additional, Zeitz, C., additional, Blauwet, L., additional, Moelmen Hansen, H.E., additional, Støylen, A., additional, Thorstensen, A., additional, Watanabe, H., additional, Yoshikawa, J., additional, Chambers, J.C., additional, Kooner, J., additional, Davies, J., additional, Loke, I., additional, Ng, L., additional, Leung, D.Y., additional, Arnold, L., additional, Coffey, S., additional, d'Arcy, J., additional, Hammond, C., additional, Mabbett, C., additional, Lima, C., additional, Loudon, M., additional, Pinheiro, N., additional, Reynolds, R., additional, Muraru, D., additional, Peluso, D., additional, Dal Bianco, L., additional, Petrovic, J., additional, Fuchs, F.D., additional, Katova, T., additional, Kaku, K., additional, Boyd, A., additional, Chia, E.M., additional, Angelo, L.C., additional, Pereira, A.C., additional, Krieger, J.E., additional, Rodrigues, S.L., additional, Paini, A., additional, Agabiti Rosei, E., additional, and Salvetti, M., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results